Brands: Diovan Hct · Valsartan + Hydrochlorothiazide
Average across 33 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Alembic Pharmaceuticals Limited | generic | 40 | SUPPLYING |
| Proficient Rx LP | repackager | 29 | SUPPLYING |
| Amneal Pharmaceuticals LLC | generic | 20 | SUPPLYING |
| Bryant Ranch Prepack | repackager | 16 | SUPPLYING |
| Zydus Lifesciences Limited | generic | 15 | SUPPLYING |
| Solco Healthcare US, LLC | unknown | 15 | SUPPLYING |
| A-S Medication Solutions | repackager | 11 | SUPPLYING |
| ScieGen Pharmaceuticals Inc | unknown | 10 | SUPPLYING |
| Macleods Pharmaceuticals Limited | generic | 8 | SUPPLYING |
| Novartis Pharmaceuticals Corporation | unknown | 5 | SUPPLYING |
| Mylan Pharmaceuticals Inc. | generic | 5 | SUPPLYING |
| Amneal Pharmaceuticals of New York LLC | generic | 5 | SUPPLYING |
| AvKARE | relabeler | 5 | SUPPLYING |
| Aurobindo Pharma Limited | generic | 4 | SUPPLYING |
| Northwind Health Company, LLC | repackager | 4 | SUPPLYING |
+ 2 more labelers
Shortages, recalls, and registration changes attached to this drug concept.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
GCMP Deviations: FDA analysis confirmed presence of trace amounts of an impurity, N-nitrosodiethylamine (NDEA) found in the API used to manufacture the product. — Recalling firm: Mylan Laboratories Limited, (Nashik FDF) — Product was distributed throughout the United States to several major distributors, including Puerto Rico.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product. — Recalling firm: Mylan Pharmaceuticals Inc. — Product was distributed throughout the United States.
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Prinston Pharmaceutical Inc — United States
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Prinston Pharmaceutical Inc — United States
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Prinston Pharmaceutical Inc — United States
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Prinston Pharmaceutical Inc — United States
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. — Recalling firm: Prinston Pharmaceutical Inc — United States
